Skip to main content
Seth Karol, MD, Pediatric Hematology & Oncology, Memphis, TN, St. Jude Children's Research Hospital

SethKarolMDMSCI(He/Him)

Pediatric Hematology & Oncology Memphis, TN

Associate Member- Leukemia/ Lymphoma Division St. Jude Children's Research Hospital

Dr. Karol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Karol's full profile

Already have an account?

Summary

  • Dr. Seth Karol is a pediatric hematologist/oncologist in Memphis, TN and is affiliated with St. Jude Children's Research Hospital. He received his medical degree from The Ohio State University College of Medicine and has been in practice as a pediatric oncologist since 2012. He has expertise in experienced acute lymphoblastic leukemia, acute myeloid leukemia, treatment side effects, early phase clinical trials, and pharmacogenomics.

Education & Training

  • University of Tennessee
    University of TennesseeFellowship, Pediatric Hematology/Oncology, 2012 - 2015
  • Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens Hospital
    Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2008 - 2011
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2008

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2012 - 2025
  • OH State Medical License
    OH State Medical License 2008 - 2012
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia. 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Venetoclax plus High-Dose Cytarabine with or Without Idarubicin Well Tolerated in Pediatric AML
    Venetoclax plus High-Dose Cytarabine with or Without Idarubicin Well Tolerated in Pediatric AMLMay 1st, 2020
  • ASH Annual Meeting Highlights St. Jude Research
    ASH Annual Meeting Highlights St. Jude ResearchDecember 6th, 2019
  • Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AML
    Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AMLJune 14th, 2019
  • Join now to see all

Hospital Affiliations